在一般人群中,血管酶转化酶I/D多态性和动脉壁厚度. 沃巴诺研究的研究
M Castellano1, M L Muiesan, D Rizzoni
1Center of Hypertension and Cardiorespiratory Risk Factors, University of Brescia, Italy.
Circulation
|June 1, 1995
概括
血管素I转化酶 (ACE) DD基因型与动脉壁厚度增加有关. 这一发现表明,ACE DD基因型可能是心血管问题的危险因素.
科学领域:
- 心血管遗传学 心血管遗传学
- 血管生物学 血管生物学
- 高血压研究 高血压研究
背景情况:
- 血管酶I转化酶 (ACE) 基因的插入/删除 (I/D) 多态,特别是D等位基因,已与心血管风险,如左心室缩等相关.
- 基因决定的氨酸-血管酶系统过度活跃可能会影响心脏和血管生长.
研究的目的:
- 为了研究ACE I/D基因型与动脉壁厚度之间的关系.
- 评估ACE I/D基因型作为亚临床动脉样硬化的潜在风险因素.
主要方法:
- 一项涉及199名年龄在50~64岁之间的普通人群的研究.
- 用B模式超声波测量动脉内心介质厚度.
- 进行了ACE I/D多态的基因定型.
主要成果:
- 该ACE DD基因型与常见动脉内心介质厚度 (P = .003) 的增加显著相关.
- 在ACE I/D基因型和动脉样硬化斑块的存在之间没有发现显著的关联.
- ACE I/D基因型与血压测量没有相关性,无论是随意还是门诊.
结论:
- 可以将ACE DD基因型确定为常见的动脉内膜-介质加厚的发展风险因素.
- 这表明ACE基因型在早期血管变化中的潜在作用有助于心血管风险.
相关概念视频
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...


